Investigation Report on China's Celecoxib Market, 2010-2019 Featuring Pfizer & Shire
DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/qjtt5c/investigation) has announced the addition of the "Investigation Report on China's Celecoxib Market, 2010-2019" report to their offering.
Currently, there are over 30 million people around the world using non-steroidal anti-inflammatory drugs (NSAIDs) as anti-inflammatory pain-relief drugs. However, many drugs under the category of NSAIDs cause gastrointestinal adverse reactions such as ulcer, perforation and bleeding. The latest research has shown that among all the NSAIDs, celecoxib reports the lowest number of cases of gastrointestinal side effects. As a kind of NASIDs, celecoxib is mainly used for osteoarthritis, rheumatoid arthritis and the adjuvant treatment of familial adenomatous polyposis. It is reported that over 100 million people in China suffer from arthritis, among which about 10% use celecoxib.
Developed by GD Searle & Pfizer, celecoxib came into the market in 1999 under the trade name of Celebrex. Ever since its debut in the US in February 1999, celecoxib has been widely used and set a record for the largest amount of prescriptions among all the new drugs in that year. Celecoxib has become the No. 1 brand of anti-rheumatic drug with a reputation as the most successful branded drug in the market.
In September 2000, celebrex (celecoxib capsule) made by Pfizer was approved by CFDA to enter China. Celecoxib develops fast then, annual sales rising from CNY 20 million in 2005 to CNY 164 million in 2014 and CAGR reaching up to 24.59% during the period of 2005-2014. Celecoxib enjoys a vast demand in China. Currently, celecoxib in the Chinese market mainly come from two companies: Pfizer Inc and Shire Plc. They monopolize the Chinese market and Pfizer has a larger market share of over 98%, sales value reaching up to CNY 162 million in 2014.
Key Topics Covered:
1 Related Concepts of Celecoxib
2 Market Profile of Celecoxib in China
3 Survey on Sales Status of Celecoxib in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Celecoxib in China, 2010-2014
5 Survey on Dosage Forms of Celecoxib in China, 2010-2014
6 Reference Price of Celecoxib in Chinese Hospitals in 2014
7 Major Manufacturers of Celecoxib in Chinese Market, 2010-2014
8 Market Outlook of Celecoxib in China, 2015-2019
Companies Mentioned
- Pfizer Inc;
- Shire Plc
For more information visit http://www.researchandmarkets.com/research/qjtt5c/investigation
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article